We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+25.75%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.5B
AUM Growth
+$474M
(+16%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
4.97%
Top 10 Holdings %
Top 10 Hldgs %
60.94%
Holding
54
New
11
Increased
8
Reduced
10
Closed
5
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$94.1M |
| 2 |
Disc Medicine
IRON
|
+$93.1M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$85.6M |
| 4 |
Vor Biopharma
VOR
|
+$80M |
| 5 |
Immunovant
IMVT
|
+$72.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAPT Therapeutics
RAPT
|
+$87.5M |
| 2 |
Abivax
ABVX
|
+$74.6M |
| 3 |
EyePoint Inc
EYPT
|
+$65.3M |
| 4 |
Structure Therapeutics
GPCR
|
+$53.4M |
| 5 |
Liquidia Corp
LQDA
|
+$48.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Abivax
ABVX
$7.68B
| $722M | 20.65% |
6,481,085
-630,511
| -9% | -$74.6M |
2023 Q4
9 quarters
|
|
2
CG Oncology
CGON
$5.48B
| $248M | 7.11% |
3,670,206
| – | – |
2024 Q1
8 quarters
|
|
3
Tango Therapeutics
TNGX
$3.74B
| $220M | 6.3% |
10,531,071
-2,231,023
| -17% | -$31.1M |
2024 Q4
5 quarters
|
|
4
Cogent Biosciences
COGT
$4.88B
| $190M | 5.45% |
4,946,894
-921,268
| -16% | -$34M |
2021 Q4
17 quarters
|
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $170M | 4.87% |
4,286,480
| – | – |
2023 Q3
10 quarters
|
|
6
Dianthus Therapeutics
DNTH
$4.18B
| $141M | 4.03% |
1,676,624
| – | – |
2024 Q4
5 quarters
|
|
7
Tyra Biosciences
TYRA
$1.29B
| $124M | 3.56% |
3,248,980
+350,877
| +12% | +$11.4M |
2021 Q4
17 quarters
|
|
|
8
Immunovant
IMVT
$5.76B
| $111M | 3.17% |
4,457,988
+2,797,055
| +168% | +$72.4M |
2025 Q4
1 quarter
|
|
|
9
BioCryst Pharmaceuticals
BCRX
$2.06B
| $105M | 3% |
+11,020,968
| New | +$85.6M |
2026 Q1
0 quarters
|
|
|
10
Mirum Pharmaceuticals
MIRM
$5.19B
| $98.1M | 2.81% |
1,062,049
+1,000,000
| +1,612% | +$94.1M |
2025 Q4
1 quarter
|
|
|
11
Vor Biopharma
VOR
$1.11B
| $96.5M | 2.76% |
+5,673,078
| New | +$80M |
2026 Q1
0 quarters
|
|
12
Spyre Therapeutics
SYRE
$7.35B
| $95.9M | 2.74% |
1,900,582
| – | – |
2025 Q3
2 quarters
|
|
13
Amylyx Pharmaceuticals
AMLX
$3.39B
| $86.8M | 2.48% |
6,243,812
| – | – |
2024 Q3
6 quarters
|
|
|
14
Disc Medicine
IRON
$2.14B
| $85.8M | 2.45% |
+1,341,862
| New | +$93.1M |
2026 Q1
0 quarters
|
|
15
Dyne Therapeutics
DYN
$2.81B
| $83.7M | 2.39% |
4,615,144
| – | – |
2023 Q1
12 quarters
|
|
16
Monte Rosa Therapeutics
GLUE
$839M
| $76M | 2.18% |
4,622,151
| – | – |
2025 Q4
1 quarter
|
|
17
Savara
SVRA
$978M
| $67.5M | 1.93% |
12,362,205
| – | – |
2023 Q3
10 quarters
|
|
18
Revolution Medicines
RVMD
$41.5B
| $56.1M | 1.6% |
576,473
+140,000
| +32% | +$14.1M |
2025 Q3
2 quarters
|
|
19
Kodiak Sciences
KOD
$5.1B
| $55.1M | 1.58% |
1,445,538
| – | – |
2023 Q4
9 quarters
|
|
20
LB Pharmaceuticals
LBRX
$1.1B
| $45.3M | 1.3% |
1,839,489
+94,474
| +5% | +$2.18M |
2025 Q3
2 quarters
|
|
21
Surrozen
SRZN
$279M
| $42.9M | 1.23% |
+1,473,101
| New | +$35.3M |
2026 Q1
0 quarters
|
|
22
ADC Therapeutics
ADCT
$185M
| $42.7M | 1.22% |
11,390,175
| – | – |
2025 Q3
2 quarters
|
|
23
Relay Therapeutics
RLAY
$3.74B
| $42.5M | 1.22% |
4,273,356
+1,053,170
| +33% | +$9.42M |
2025 Q3
2 quarters
|
|
24
Fulcrum Therapeutics
FULC
$280M
| $40.3M | 1.15% |
5,250,000
| – | – |
2024 Q3
6 quarters
|
|
25
Biohaven
BHVN
$1.65B
| $39.2M | 1.12% |
4,631,317
| – | – |
2025 Q4
1 quarter
|
|
Similar funds
CCMIC
TCG Crossover Management's Q1 2026 Portfolio in Review
As of Q1 2026, TCG Crossover Management held 54 positions worth $3.5B, up 16% from $3.02B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
TCG Crossover Management deployed $174M of net new capital in Q1 2026, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Disc Medicine: 1,341,862 shares worth $85.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Abivax, an estimated $74.6M trimmed.
- TCG Crossover Management's largest Q1 2026 buy was Disc Medicine: 1,341,862 shares worth $85.8M.
- TCG Crossover Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $94.1M increase.
- TCG Crossover Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $74.6M.
- TCG Crossover Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $87.5M.
- TCG Crossover Management's ten largest holdings make up 61% of its $3.5B portfolio in Q1 2026.
- TCG Crossover Management opened 11 new positions and closed 5 in Q1 2026.
- TCG Crossover Management's portfolio value rose 16% quarter-over-quarter to $3.5B.
Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.